These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 9005348

  • 1. [High dosage tranylcypromine treatment of "therapy refractory" depressions].
    Schmauss M.
    Nervenarzt; 1996 May; 67(5):390-3. PubMed ID: 9005348
    [Abstract] [Full Text] [Related]

  • 2. Refractory depression treated with high doses of monoamine oxidase inhibitor.
    Guze BH, Baxter LR, Rego J.
    J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
    [Abstract] [Full Text] [Related]

  • 3. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH.
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [Abstract] [Full Text] [Related]

  • 4. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M, Pilhatsch M, Bauer M, Köberle U, Ricken R, Janssen G, Ulrich S, Bschor T.
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [Abstract] [Full Text] [Related]

  • 5. Pindolol augmentation of tranylcypromine in psychotic depression.
    Kraus RP.
    J Clin Psychopharmacol; 1997 Jun; 17(3):225-6. PubMed ID: 9169970
    [No Abstract] [Full Text] [Related]

  • 6. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF, Thase ME.
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract] [Full Text] [Related]

  • 7. The role of monoamine oxidase inhibitors in depression treatment guidelines.
    Thase ME.
    J Clin Psychiatry; 2012 Feb; 73 Suppl 1():10-6. PubMed ID: 22951237
    [Abstract] [Full Text] [Related]

  • 8. [Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?].
    Radat F, Berlin I, Varoquaux O, Ferreri M, Puech A.
    Ann Med Psychol (Paris); 1996 Jun; 154(3):204-6. PubMed ID: 8766502
    [No Abstract] [Full Text] [Related]

  • 9. Drug combinations in the treatment of refractory depression: a review.
    Stern SL, Mendels J.
    J Clin Psychiatry; 1981 Oct; 42(10):368-73. PubMed ID: 6116699
    [Abstract] [Full Text] [Related]

  • 10. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases.
    Quante A, Zeugmann S.
    J Clin Psychopharmacol; 2012 Aug; 32(4):572-4. PubMed ID: 22760351
    [No Abstract] [Full Text] [Related]

  • 11. [Practical considerations in initial treatment].
    Allilaire JF.
    Encephale; 1995 Mar; 21 Spec No 2():23-9. PubMed ID: 7588174
    [Abstract] [Full Text] [Related]

  • 12. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression.
    Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T.
    Biol Psychiatry; 1996 Jul 15; 40(2):151-3. PubMed ID: 8793048
    [No Abstract] [Full Text] [Related]

  • 13. High-dosage tranylcypromine in refractory depression.
    Pearlman C.
    J Clin Psychiatry; 1987 Oct 15; 48(10):424-5. PubMed ID: 3667544
    [No Abstract] [Full Text] [Related]

  • 14. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate.
    Nolen WA, van den Broek WW, Birkenhäger TK.
    Am J Psychiatry; 2007 Mar 15; 164(3):524; author reply 524. PubMed ID: 17329480
    [No Abstract] [Full Text] [Related]

  • 15. High dose tranylcypromine therapy for refractory depression.
    Amsterdam JD, Berwish NJ.
    Pharmacopsychiatry; 1989 Jan 15; 22(1):21-5. PubMed ID: 2710808
    [Abstract] [Full Text] [Related]

  • 16. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
    Tulen JH, Volkers AC, van den Broek WW, Bruijn JA.
    J Clin Psychopharmacol; 2006 Oct 15; 26(5):542-4. PubMed ID: 16974207
    [No Abstract] [Full Text] [Related]

  • 17. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP, Gleiter CH, Möller HJ.
    Nervenarzt; 1996 May 15; 67(5):339-47. PubMed ID: 9005342
    [Abstract] [Full Text] [Related]

  • 18. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ, Sclar DA, Culpepper L, Flockhart DA, Hirschfeld RM, Thase ME, VanDenBerg CM.
    J Clin Psychiatry; 2012 May 15; 73 Suppl 1():42-5. PubMed ID: 22951242
    [No Abstract] [Full Text] [Related]

  • 19. [Prognostic value of pharmaco-EEG in depression treated with moclobemide].
    Wiśniewski G, Jakitowicz J, Nowicki Z, Pankiewicz P.
    Psychiatr Pol; 2002 May 15; 36(6 Suppl):93-8. PubMed ID: 12647427
    [Abstract] [Full Text] [Related]

  • 20. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.
    Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL.
    J Clin Psychopharmacol; 1993 Oct 15; 13(5):312-20. PubMed ID: 8227489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.